Andere talen Spyre Therapeutics, Inc.

Aandelen

SYRE

US00773J2024

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
35,58 ^USD	+3,70%		-7,80%	+65,33%

26/03	SPYRE THERAPEUTICS, INC. : Stifel Nicolaus ontvangt een koopadvies	ZM
01/03	SPYRE THERAPEUTICS, INC. : Wells Fargo Securities positief over het aandeel	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Spyre Therapeutics Announces Grants of Inducement Awards	01/04
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding	18/03
North American Morning Briefing : Powell Still in -2-	07/03
Spyre Therapeutics Announces Grants of Inducement Awards	04/03
North American Morning Briefing : Stock Futures -2-	04/03
Spyre Therapeutics Announces Grants of Inducement Awards	01/03
Spyre Therapeutics: Q4 Earnings Snapshot	29/02
Spyre Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Spyre Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference	26/02
Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn s and Colitis Organisation	09/02
Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors	06/02
Spyre Therapeutics, Inc. Announces Board Changes	05/02
Spyre Therapeutics Announces Grants of Inducement Awards	02/02
Spyre Therapeutics, Inc. announced that it has received $180 million in funding from a group of investors	27/12
Spyre Therapeutics Announces Grants of Inducement Awards	22/12
Spyre Therapeutics Agrees to Sell Shares in Private Placement for Expected Gross Proceeds of About $180 Million	08/12
Spyre Therapeutics, Inc. announced that it expects to receive $180 million in funding from a group of investors	07/12
Spyre Therapeutics to Present at Upcoming Investor Conference	29/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Spyre Therapeutics, Inc.

Aandelen

SYRE

US00773J2024

Andere talen

Filters